Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa
Phase 1
Completed
- Conditions
- Epidermolysis Bullosa
- Registration Number
- NCT00014729
- Lead Sponsor
- University of North Carolina
- Brief Summary
OBJECTIVES:
I. Determine the safety of isotretinoin in patients with recessive dystrophic epidermolysis bullosa.
- Detailed Description
PROTOCOL OUTLINE:
Patients receive oral isotretinoin daily for 8 months in the absence of disease progression or unacceptable toxicity.
Completion date provided represents the completion date of the grant per OOPD records
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method